Search results for " 7"

showing 10 items of 1950 documents

Multiple levels of MHC class I down-regulation by ras oncogenes.

1996

A number of tumours and oncogene transformed cells displayed reduced MHC class I surface expression which seemed to enable their escape from immune surveillance. To test whether oncogenic activation is directly involved in suppressing MHC class I expression, a model of inducible oncogene expression was chosen. Mouse fibroblasts transfected with different oncogenes expressed under the control of the dexamethasone-inducible MMTV promoter were analysed in the presence and absence of hormone for the mRNA and protein expression of MHC class I molecules as well as the respective oncogenes. Immunofluorescence analyses demonstrated an inverse association of MHC class I and oncogene expression after…

CD74Transcription GeneticImmunologyCD1Down-RegulationGene ExpressionC-C chemokine receptor type 7TransfectionDexamethasoneMiceAntigenMHC class IAnimalsRNA Processing Post-TranscriptionalPromoter Regions GeneticMessenger RNAbiologyOncogeneHistocompatibility Antigens Class IGeneral Medicine3T3 CellsMHC restrictionMolecular biologyGenes rasMammary Tumor Virus MouseAntigens Surfacebiology.proteinImmunoglobulin Heavy Chainsbeta 2-MicroglobulinScandinavian journal of immunology
researchProduct

Search for CP violation using T-odd correlations in D-0 -> K+K-pi(+)pi(-) decays

2014

A search for $CP$ violation using $T$-odd correlations is performed using the four-body $D^0 \to K^+K^-\pi^+\pi^-$ decay, selected from semileptonic $B$ decays. The data sample corresponds to integrated luminosities of $1.0\,\text{fb}^{-1}$ and $2.0\,\text{fb}^{-1}$ recorded at the centre-of-mass energies of 7 TeV and 8 TeV, respectively. The $CP$-violating asymmetry $a_{CP}^{T\text{-odd}}$ is measured to be $(0.18\pm 0.29\text{(stat)}\pm 0.04\text{(syst)})\%$. Searches for $CP$ violation in different regions of phase space of the four-body decay, and as a function of the $D^0$ decay time, are also presented. No significant deviation from the $CP$ conservation hypothesis is found.

CP violation Charm physics Hadron-Hadron Scattering Flavor physics14.40.Lb01 natural sciencesSettore FIS/04 - Fisica Nucleare e SubnucleareHigh Energy Physics - ExperimentFlavor physics[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]ASTRONOMY & ASTROPHYSICSQCmedia_commonCharm physicsPhysicsHadronic decays of charmed mesonCharm physics; CP violation; Flavor physics; Hadron-Hadron ScatteringPhysicsPHYSICS PARTICLES & FIELDSParticle physicsCharge conjugation parity time reversal and other discrete symmetrieDecay timeCP violationPhysical Sciences13.25.FtCP violationFísica nuclearLHCParticle Physics - ExperimentTRIPLE-PRODUCT CORRELATIONSPACS: 13.25.Ft 11.30.ErCharm physicNuclear and High Energy PhysicsParticle physicsmedia_common.quotation_subjectLHCb - Abteilung HofmannHadronsAsymmetryNONuclear physicsTheoryofComputation_ANALYSISOFALGORITHMSANDPROBLEMCOMPLEXITY0103 physical sciencesPiSDG 7 - Affordable and Clean Energy010306 general physicsLarge Hadron Collider (France and Switzerland)Science & Technology/dk/atira/pure/sustainabledevelopmentgoals/affordable_and_clean_energyHadron-Hadron Scatteringhep-ex010308 nuclear & particles physicsGran Col·lisionador d'HadronsCharm physics; CP violation; Flavor physics; Hadron-Hadron Scattering; Nuclear and High Energy PhysicsBABAR detectorHEPANGULAR-CORRELATIONSLHCbFlavor physicPhase spaceBaBar11.30.ErFísica de partículesExperimentsCharmed mesons (|C|>0 B=0)
researchProduct

Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-γ1-driven activation of mTOR/p70S6-kinase pathway

2009

In chronic myeloid leukemia, activation of the phosphoinositide 3-kinase (PI3K)/Akt pathway is crucial for survival and proliferation of leukemic cells. Essential downstream molecules involve mammalian target of rapamycin (mTOR) and S6-kinase. Here, we present a comprehensive analysis of the molecular events involved in activation of these key signaling pathways. We provide evidence for a previously unrecognized phospholipase C-gamma1 (PLC-gamma1)-controlled mechanism of mTOR/p70S6-kinase activation, which operates in parallel to the classical Akt-dependent machinery. Short-term imatinib treatment of Bcr-Abl-positive cells caused dephosphorylation of p70S6-K and S6-protein without inactivat…

Cancer ResearchBlotting WesternMedizinFusion Proteins bcr-ablApoptosisProtein Serine-Threonine KinasesBiologyPiperazinesMiceLeukemia Myelogenous Chronic BCR-ABL Positivehemic and lymphatic diseasesGeneticsAnimalsHumansRNA Small InterferingProtein Kinase InhibitorsMolecular BiologyProtein kinase BCAMKPI3K/AKT/mTOR pathwayPhospholipase C gammaCell growthKinaseTOR Serine-Threonine KinasesRPTORIntracellular Signaling Peptides and ProteinsRibosomal Protein S6 Kinases 70-kDaCell biologyEnzyme ActivationPyrimidinesBenzamidesembryonic structuresImatinib MesylateCancer researchPhosphorylationSignal transductionProto-Oncogene Proteins c-aktSignal TransductionOncogene
researchProduct

Cleavage of CD95 by matrix metalloproteinase-7 induces apoptosis resistance in tumour cells

2004

The ability of tumour cells to resist apoptosis-inducing signals by cytotoxic T cells may decide the success or failure of tumour elimination. An important effector of apoptosis is the CD95/CD95 ligand system (APO-1/Fas) that mediates perforin-independent cytotoxic T-cell killing of tumour cells. We propose a new strategy by which tumour cells can resist CD95-induced apoptosis. We identified matrix metalloproteinase-7, MMP-7 (Martilysin), as the first physiologically relevant protease that can specifically cleave CD95. MMP-7 is of unique importance because it is produced by the tumour cells themselves at early stages of tumour development. Microsequencing of the positions in CD95 cleaved by…

Cancer ResearchEffectorApoptosishemic and immune systemschemical and pharmacologic phenomenaBiologyMatrix metalloproteinaseFas receptorCleavage (embryo)medicine.disease_causeCell biologyApoptosisMatrix Metalloproteinase 7hemic and lymphatic diseasesTumor Cells CulturedGeneticsExtracellularmedicineHumansCytotoxic T cellfas Receptorbiological phenomena cell phenomena and immunityCarcinogenesisMolecular BiologyOncogene
researchProduct

Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor.

2014

Small cell lung cancer (SCLC) is an aggressive disease with high mortality, and the identification of effective pharmacological strategies to target SCLC biology represents an urgent need. Using a high-throughput cellular screen of a diverse chemical library, we observe that SCLC is sensitive to transcription-targeting drugs, in particular to THZ1, a recently identified covalent inhibitor of cyclin-dependent kinase 7. We find that expression of super-enhancer-associated transcription factor genes, including MYC family proto-oncogenes and neuroendocrine lineage-specific factors, is highly vulnerability to THZ1 treatment. We propose that downregulation of these transcription factors contribut…

Cancer ResearchLung NeoplasmsTranscription GeneticMolecular Sequence DataAntineoplastic AgentsBiologyBioinformaticsArticleMiceSuper-enhancerDownregulation and upregulationCell Line TumorMedicineAnimalsHumansEnzyme InhibitorsneoplasmsTranscription factorRegulation of gene expressionbusiness.industryCell BiologyNeoplasms ExperimentalSequence Analysis DNASmall Cell Lung CarcinomaXenograft Model Antitumor AssayshumanitiesCyclin-Dependent Kinasesrespiratory tract diseasesHigh-Throughput Screening AssaysGene Expression Regulation NeoplasticOncologyCovalent bondCancer cellCancer researchNon small cellSmall Cell Lung CarcinomaCyclin-dependent kinase 7businessTranscription Factor GeneCDK12Transcription FactorsCancer cell
researchProduct

Cytogenetic analysis of epithelial renal-cell tumors: Relationship with a new histopathological classification

1993

Renal-cell carcinomas (RCC) are clinically, histologically and cytogenetically very heterogeneous. The present histological WHO classification shows no clear correlation between histologic subtypes and specific chromosomal abnormalities. In 1986, a new classification was proposed by Thoenes and Storkel based on the cell type from which the tumor arises. They distinguish S cell types: clear-cell, chromophilic, chromophobic, ductus Bellini and oncocytic. Results of 105 primary tumors show that, in this new classification, there is a correlation between different subtypes of renal-cell tumor and specific chromosomal abnormalities at a microscopic and/or molecular level. The clear-cell compact …

Cancer ResearchPathologymedicine.medical_specialtyMonosomyCell typeCARCINOMAChromosome DisordersHistogenesisBiologyPolysomy 7Loss of heterozygositymedicineHumansCarcinoma Renal CellChromosome AberrationsChromosome 7 (human)PolysomyPloidiesABNORMALITIESCytogeneticsDNA Neoplasmmedicine.diseaseKidney NeoplasmsONCOCYTOMASOncologyTISSUEKaryotypingInternational Journal of Cancer
researchProduct

Human leukocyte elastase counteracts matrix metalloproteinase-7 induced apoptosis resistance of tumor cells.

2008

Matrix metalloproteinase-7 (MMP-7/Matrilysin) is a component of the tumor microenvironment associated with malignant progression. Its expression in tumors protects tumor cells from CD95-mediated apoptosis and the cytotoxic activity of tumor specific CD8(+) T cells. In the present study, we show that human leukocyte elastase (HLE) secreted by polymorphonuclear leukocytes cleaves MMP-7 resulting in loss of enzymatic activity. The anti-apoptotic effect of MMP-7 is reduced in the presence of HLE for CD95-, doxorubicin- and CTL-mediated apoptosis. Our data indicates that HLE may be a natural inactivator of MMP-7 which can counteract MMP-7-induced apoptosis resistance.

Cancer ResearchTumor microenvironmentbiologyChemistryNeutrophilsApoptosisMatrix metalloproteinaseFas receptorCell biologyOncologyApoptosisDoxorubicinNeutrophil elastaseMatrix Metalloproteinase 7NeoplasmsCancer researchbiology.proteinCytotoxic T cellHumanssense organsMatrilysinLeukocyte ElastaseCD8Cells CulturedT-Lymphocytes CytotoxicCancer letters
researchProduct

The Norwegian childhood cancer biobank

2021

Background - The rapidly expanding era of “omics” research is highly dependent on the availability of quality-proven biological material, especially for rare conditions such as pediatric malignancies. Professional biobanks provide such material, focusing on standardized collection and handling procedures, distinctive quality measurements, traceability of storage conditions, and accessibility. For pediatric malignancies, traditional tumor biobanking is challenging due to the rareness and limited amount of tissue and blood samples. The higher molecular heterogeneity, lower mutation rates, and unique genomic landscapes, however, renders biobanking of this tissue even more crucial. Aim - The ai…

Cancer Researchmedicine.medical_specialtybusiness.industryChildhood cancerVDP::Medisinske Fag: 700::Basale medisinske odontologiske og veterinærmedisinske fag: 710NorwegianSafeguardingOmicsUniversity hospitalBiobankBiological materialslanguage.human_languageVDP::Medical disciplines: 700::Basic medical dental and veterinary science disciplines: 710OncologyInformed consentFamily medicinemedicinelanguagebusiness
researchProduct

Candida bloodstream infections in intensive care units: Analysis of the extended prevalence of infection in intensive care unit study

2011

Objectives: To provide a global, up-to-date picture of the prevalence, treatment, and outcomes of Candida bloodstream infections in intensive care unit patients and compare Candida with bacterial bloodstream infection. Design: A retrospective analysis of the Extended Prevalence of Infection in the ICU Study (EPIC II). Demographic, physiological, infection-related and therapeutic data were collected. Patients were grouped as having Candida, Gram-positive, Gram-negative, and combined Candida/bacterial bloodstream infection. Outcome data were assessed at intensive care unit and hospital discharge. Setting: EPIC II included 1265 intensive care units in 76 countries. Patients: Patients in partic…

Candida albicanMaleAntifungal AgentsIron metabolism Pathogenesis and modulation of inflammation [IGMD 7]Settore MED/41 - AnestesiologiaCritical Care and Intensive Care Medicinelaw.inventionEchinocandinschemistry.chemical_compound0302 clinical medicineRetrospective StudieCaspofunginlawCandida albicansPrevalenceAntifungal Agent030212 general & internal medicineCandida albicansFluconazoleMESH: SepsisFungemiaintensive careMedicine(all)MESH: AgedCross Infection0303 health scienceseducation.field_of_studyMESH: Middle AgedfungemiabiologyCandidiasisMiddle AgedIntensive care unitMESH: Candidiasisbacteremia; epidemiology; fungemia; intensive care; outcome assessment (health care); Aged; Antifungal Agents; Candida albicans; Candidiasis; Cross Infection; Echinocandins; Female; Fluconazole; Humans; Intensive Care Units; Lipopeptides; Male; Middle Aged; Prevalence; Retrospective Studies; Sepsis; Critical Care and Intensive Care Medicine3. Good healthIntensive Care Unitsbacteremia epidemiology fungemia intensive care outcome assessment (health care)CandidiasiMESH: FluconazoleepidemiologyFemaleHumanmedicine.drugmedicine.medical_specialtySepsiIntensive Care UnitPopulationLipopeptides03 medical and health sciencesSepsisIntensive caremedicineHumansEchinocandinbacteremiaIntensive care medicineeducationMESH: PrevalenceAgedRetrospective Studiesoutcome assessment (health care)MESH: Humans030306 microbiologybusiness.industryMESH: Candida albicansMESH: EchinocandinsMESH: Cross InfectionMESH: Retrospective Studies[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: Antifungal Agentsmedicine.diseasebiology.organism_classificationMESH: MalechemistryBacteremiaMESH: Intensive Care UnitsCaspofunginbusinessMESH: FemaleFluconazole
researchProduct

Building an advocacy model to improve the dementia-capability of health plans in California

2021

Background Given the high and growing prevalence of Alzheimer's disease and related dementias, and the intensity of this population's care needs, it is imperative that healthcare systems increase their capacity to effectively serve people living with dementia (PLwD). The Dementia Cal MediConnect (Dementia CMC) project proposes an advocacy model that may foster dementia-capable systems change. Methods The Dementia CMC project was a 5-year partnership (2013-2018) between local Alzheimer's organizations and 10 managed care health plans (HPs) in California's duals demonstration. It used an advocacy model with the following steps: (1) Identify dementia-capable best practices to set as systems ch…

Capacity BuildingSystems AnalysisReferralBest practicePopulationPatient AdvocacyPublic-Private Sector PartnershipsCaliforniaNursingAlzheimer DiseaseHumansMedicineDementiaBusiness caseeducationeducation.field_of_studyGovernmentbusiness.industrymedicine.diseaseOrganizational InnovationGeneral partnershipVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Geriatri: 778Managed careDementiasense organsGeriatrics and GerontologybusinessDelivery of Health Care
researchProduct